Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

Read on to learn more about canine allergies and dog allergy medications ... also known as atopic dermatitis, are estimated to affect 10-15 percent of dogs. Affected dogs often experience seasonal ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

This product feels really nice on my skin and has a positive, moisturizing and calming effect. I would highly recommend." Dr.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

About Atopic Dermatitis Atopic Dermatitis (AD), a form of eczema, is a chronic inflammatory skin condition characterized by areas of dry skin that are red and intensely itchy. Rigorous moisturizing ...